Novo Nordisk A/S slashed its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, as the company loses ground to Eli Lilly & Co. in the obesity market. The shares plunged.
Novo Lowers Forecast as Weight-Loss Drug Sales Fall Short
Date:
More like thisRelated
Tampa RV giant Lazydays to delist from Nasdaq
Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...
Granite Geek: New Hampshire might get access to ‘balcony solar’
I had solar panels put on my roof six...
TSX Today: What to Watch for in Stocks on Monday, November 10
Despite firm gold and silver prices, Canadian stocks...
While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!
As market-wide fear grips the sector, the Binance Coin...